Eli Lilly is well on its way to the trillion-dollar club. The stock price is up 30% so far this year; with a total ...
Zacks Investment Research on MSN
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
Eli Lilly and Company’s LLY stock crossed the $1000 per share mark for the first time on Nov. 12, reaching new highs. It is ...
Zacks Investment Research on MSN
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY stock has risen 18% in a month, driven mainly by a stellar third-quarter performance. Also, ...
Mirikizumab (Omvoh) is effective in inducing a clinical response in adults with moderate-to-severe ulcerative colitis and ...
Ulcerative colitis (UC) is one of the most common inflammatory bowel diseases, a lifelong condition that can cause chronic ...
Interleukin-23 (IL-23) plays a pivotal role in the complex pathogenesis of both ulcerative colitis and Crohn's disease, making it a promising therapeutic target.1 Mirikizumab is a humanised IgG4 ...
Eli Lilly said federal regulators have approved of a single-injection, once-monthly maintenance regimen in the U.S. for its ulcerative colitis treatment Omvoh. The pharmaceutical company said Monday ...
AUSTIN, Texas, Oct. 26, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company is ...
Bottom Line: Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL) to discontinue daily therapy and potentially ...
Week held in Berlin, Germany, an informative session explored emerging approaches for the management of ulcerative colitis (UC), ranging from surgical interventions to updated treatment guidelines and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback